Inpharmatica of the UK has appointed a team of medicinal chemists that will operate at its new Cambridge laboratory, acquired in June from Arqule.
The company, which specialises in informatics and drug lead optimisation services, said the recruitment will help it shore up its chemistry expertise as it embarks on its in-house research activities.
The team will be headed by Dr Andrew Ayscough, who was formerly director of research at British Biotech (which has just announced swingeing cuts in its research projects), where he was responsible for the direction of the firm's medicinal chemistry programmes. He will serve as Director of Chemistry at Inpharmatica.
The remainder of the medicinal chemistry team has come from Millennium Pharmaceuticals in Cambridge, UK. The latter company recently said that it would be closing down its operations at that site.
Commenting on the announcement, Dr Malcolm Weir, CEO of Inpharmatica, said: "Andrew and his new team will bring much experience to our rapidly advancing internal discovery programmes. Their recruitment fulfils a key milestone in the development of Inpharmatica's internal drug discovery capability and is a further step in the Company's drive to develop new drugs."